Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Sell

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Buy

Wall Street Data Solutions Rating

Sell

C

Vaxcyte, Inc. Common Stock (PCVX)

Biological Products, (no Disgnostic Substances)

https://www.vaxcyte.com

Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-XP, VAX-A1, and VAX-PG.

825 INDUSTRIAL ROAD, STE. 300
SAN CARLOS, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/12/2020

Market Cap

8,827,792,950

Shares Outstanding

95,150,000

Weighted SO

95,153,909

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

LRMR --.--%

SNDX --.--%

MRUS --.--%

STRO --.--%

ACLX --.--%

VTYX --.--%

IMCR --.--%

DICE --.--%

NUVL --.--%

Beta

0.9720

Last Div

0.0000

Range

44.2-87.71

Chg

0.6550

Avg Vol

738772

Mkt Cap

8827792950

Exch

NASDAQ

Country

US

Phone

650 837 0111

DCF Diff

74.6500

DCF

3.7900

Div Yield

0.0000

P/S

611.0891

EV Multiple

-17.0036

P/FV

4.6696

Div Yield %

0.0000

P/E

-18.6537

PEG

1.5296

Payout

0.0000

Current Ratio

17.8821

Quick Ratio

17.8821

Cash Ratio

6.2606

DSO

451.8663

DIO

0.0000

Op Cycle

451.8663

DPO

318.4204

CCC

133.4458

Gross Margin

0.1695

Op Margin

-34.7608

Pretax Margin

-34.4170

Net Margin

-34.4170

Eff Tax Rate

0.0145

ROA

-0.2382

ROE

-0.3007

ROCE

-0.2505

NI/EBT

1.0000

EBT/EBIT

0.9901

EBIT/Rev

-34.7608

Debt Ratio

0.0123

D/E

0.0129

LT Debt/Cap

0.0091

Total Debt/Cap

0.0127

Int Coverage

-46.7992

CF/Debt

-18.2509

Equity Multi

1.0509

Rec Turnover

0.8078

Pay Turnover

1.1463

Inv Turnover

0.0000

FA Turnover

0.0946

Asset Turnover

0.0069

OCF/Share

-3.9817

FCF/Share

-5.0209

Cash/Share

12.3890

OCF/Sales

-32.3187

FCF/OCF

1.2610

CF Coverage

-18.2509

ST Coverage

-64.0170

CapEx Coverage

-3.8314

Div&CapEx Cov

-3.8314

P/BV

4.6696

P/B

4.6696

P/S

611.0891

P/E

-18.6537

P/FCF

-14.9946

P/OCF

-19.8648

P/CF

-19.8648

PEG

1.5296

P/S

611.0891

EV Multiple

-17.0036

P/FV

4.6696

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Sep 05, 03:58 Vaxcyte Announces Pricing of $1.3 Billion Public Offering Benzinga Jan 05, 13:52 "Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales Benzinga Dec 07, 15:27 Vaccine Player Vaxcyte Can Potentially Disrupt Pfizer's 20-Plus-Year Near Monopoly, Says Analyst GlobeNewswire Inc. Dec 04, 18:35 VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate GlobeNewswire Inc. Dec 04, 18:35 VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate GlobeNewswire Inc. Dec 04, 18:35 VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate GlobeNewswire Inc. Dec 04, 18:35 VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate GlobeNewswire Inc. Dec 04, 18:35 VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate GlobeNewswire Inc. Dec 04, 18:35 VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate GlobeNewswire Inc. Dec 04, 18:35 VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate GlobeNewswire Inc. Dec 04, 18:35 VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate GlobeNewswire Inc. Nov 09, 08:30 Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

Revenue Product Segmentation